Yinwei Ho
Overview
Explore the profile of Yinwei Ho including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
853
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Agarwal P, Zhang B, Ho Y, Cook A, Li L, Mikhail F, et al.
Blood
. 2016 Dec;
129(8):1008-1020.
PMID: 28011678
Tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) has limited efficacy against leukemia stem cells (LSC) responsible for disease propagation, and most CML patients require continued TKI treatment...
2.
Irvine D, Zhang B, Kinstrie R, Tarafdar A, Morrison H, Campbell V, et al.
Sci Rep
. 2016 May;
6:25476.
PMID: 27157927
Targeting the Hedgehog (Hh) pathway represents a potential leukaemia stem cell (LSC)-directed therapy which may compliment tyrosine kinase inhibitors (TKIs) to eradicate LSC in chronic phase (CP) chronic myeloid leukaemia...
3.
Zhang B, Li L, Ho Y, Li M, Marcucci G, Tong W, et al.
J Clin Invest
. 2016 Feb;
126(3):975-91.
PMID: 26878174
Chronic myelogenous leukemia (CML) results from transformation of a long-term hematopoietic stem cell (LTHSC) by expression of the BCR-ABL fusion gene. However, BCR-ABL-expressing LTHSCs are heterogeneous in their capacity as...
4.
Qi J, Singh S, Hua W, Cai Q, Chao S, Li L, et al.
Cell Stem Cell
. 2015 Sep;
17(5):597-610.
PMID: 26387755
Acute myeloid leukemia (AML) is driven and sustained by leukemia stem cells (LSCs) with unlimited self-renewal capacity and resistance to chemotherapy. Mutation in the TP53 tumor suppressor is relatively rare...
5.
Bowers M, Zhang B, Ho Y, Agarwal P, Chen C, Bhatia R
Blood
. 2015 Mar;
125(17):2678-88.
PMID: 25742698
Hematopoietic stem cells (HSCs) reside in regulatory niches in the bone marrow (BM). Although HSC niches have been extensively characterized, the role of endosteal osteoblasts (OBs) in HSC regulation requires...
6.
Wang L, Li L, Li L, Chu S, Shiang K, Li M, et al.
Blood
. 2014 Dec;
125(8):1302-13.
PMID: 25515961
MicroRNAs (miRNAs) are key regulators of hematopoietic cell differentiation and may contribute to altered growth of leukemic stem cells. Using microarray-based miRNA profiling, we found that miRNA 486 (miR-486) is...
7.
Li L, Osdal T, Ho Y, Chun S, McDonald T, Agarwal P, et al.
Cell Stem Cell
. 2014 Oct;
15(4):431-446.
PMID: 25280219
The FLT3-ITD mutation is frequently observed in acute myeloid leukemia (AML) and is associated with poor prognosis. In such patients, FLT3 tyrosine kinase inhibitors (TKIs) are only partially effective and...
8.
Cook A, Li L, Ho Y, Lin A, Li L, Stein A, et al.
Blood
. 2014 Mar;
123(18):2826-37.
PMID: 24668492
Acute myeloid leukemia (AML) is sustained by small populations of leukemia stem cells (LSCs) that can resist available treatments and represent important barriers to cure. Although previous studies have shown...
9.
Li L, Wang L, Li L, Wang Z, Ho Y, McDonald T, et al.
Cancer Cell
. 2012 Feb;
21(2):266-81.
PMID: 22340598
BCR-ABL tyrosine kinase inhibitors (TKI) fail to eliminate quiescent leukemia stem cells (LSC) in chronic myelogenous leukemia (CML). Thus, strategies targeting LSC are required to achieve cure. We show that...
10.
Zhang B, Strauss A, Chu S, Li M, Ho Y, Shiang K, et al.
Cancer Cell
. 2010 May;
17(5):427-42.
PMID: 20478526
Imatinib mesylate (IM) induces remission in chronic myelogenous leukemia (CML) patients but does not eliminate leukemia stem cells (LSCs), which remain a potential source of relapse. Here we investigated the...